Sorry, you need to enable JavaScript to visit this website.
Home Our Science Focus Areas Pipeline and Clinical Trials

CANCER DRUG DEVELOPMENT PIPELINE

Oncology Drug Pipeline & Cancer Clinical Trials

Pfizer Oncology is committed to discovering, investigating, and developing transformative therapies that improve the outlook for cancer patients worldwide.

Our strong pipeline—one of the most robust in the industry—includes biologics, small molecules, immunotherapies, and biosimilars, and is centered on exploring a wide array of approaches across many tumor types. We seek to translate the most innovative science into meaningful breakthrough medicines that redefine life with cancer for patients.

 

Filter Options

    Development Phase

    Areas of Focus

    Submission Type

    Compound Type

    Project Status

    Sort by

    PF-06873600 | New project

    • Phase 1
    • Oncology
    • New Molecular Entity
    • Small Molecule
    • Discontinued
    Breast Cancer Metastatic

    CDK 2,4,6 Inhibitor

    PF-07284890 | New project

    • Phase 1
    • Oncology
    • New Molecular Entity
    • Small Molecule
    • Discontinued
    Melanoma

    BRAF BP kinase Inhibitor

    PF-07263689 | New project

    • Phase 1
    • Oncology
    • New Molecular Entity
    • Biologic
    • Discontinued
    Solid Tumors (Biologic)

    OBIR-2 Therapeutic

    PF-07799544 | Project advanced

    • Phase 1
    • Oncology
    • New Molecular Entity
    • Small Molecule
    • Current
    Solid Tumors

    MEK Brain Penetrant Inhibitor

    PF-07220060 | New project

    • Phase 1
    • Oncology
    • Product Enhancement
    • Small Molecule
    • Current
    Prostate Cancer

    CDK4 inhibitor

    PF-07104091 | New project

    • Phase 1
    • Oncology
    • Product Enhancement
    • Small Molecule
    • Current
    Ovarian Cancer

    CDK2 inhibitor

    PF-07799933 BRAF Class 2 | New project

    • Phase 1
    • Oncology
    • New Molecular Entity
    • Small Molecule
    • Current
    Cancer

    BRAF Class 1 and Class 2 inhibitor

    PF-07104091 + PF-07220060 | New project

    • Phase 1
    • Oncology
    • New Molecular Entity
    • Small Molecule
    • Current
    Breast Cancer Metastatic

    CDK2 + CDK4 inhibitors

    PF-07265028 | New project

    • Phase 1
    • Oncology
    • New Molecular Entity
    • Small Molecule
    • Current
    Solid Tumors

    HPK1 Inhibitor

    PF-07260437 | New project

    • Phase 1
    • Oncology
    • New Molecular Entity
    • Biologic
    • Current
    Breast Cancer Metastatic (Biologic)

    B7H4-CD3 Bispecific

    PF-07257876 | New project

    • Phase 1
    • Oncology
    • New Molecular Entity
    • Biologic
    • Current
    NSCLC (Biologic)

    CD47xPDL1 Bispecific

    PF-07284892 | New project

    • Phase 1
    • Oncology
    • New Molecular Entity
    • Small Molecule
    • Current
    Cancer

    SHP2 tyrosine phosphatase Inhibitor

    PF-07248144 | New project

    • Phase 1
    • Oncology
    • New Molecular Entity
    • Small Molecule
    • Current
    Breast Cancer Metastatic

    KAT6A Epigenetic modifier

    PF-07104091 | New project

    • Phase 1
    • Oncology
    • New Molecular Entity
    • Small Molecule
    • Current
    Breast Cancer Metastatic

    CDK2 Inhibitor

    PF-07265807 | New project

    • Phase 1
    • Oncology
    • New Molecular Entity
    • Small Molecule
    • Current
    Solid Tumors

    AXL/MERTK Inhibitor

    PF-07220060 | New project

    • Phase 1
    • Oncology
    • New Molecular Entity
    • Small Molecule
    • Current
    Breast Cancer Metastatic

    CDK4 Inhibitor

    PF-07209960 | New project

    • Phase 1
    • Oncology
    • New Molecular Entity
    • Biologic
    • Current
    Solid Tumors (Biologic)

    interleukin 15 (IL15) Activator

    PF-06940434 | New project

    • Phase 1
    • Oncology
    • New Molecular Entity
    • Biologic
    • Current
    Solid Tumors (Biologic)

    Integrin alpha-V/beta-8 Antagonist

    PF-07062119 | New project

    • Phase 1
    • Oncology
    • New Molecular Entity
    • Biologic
    • Current
    Advanced/Metastatic Gastrointestinal Cancer (Biologic)

    GUCY2c CD3 Bispecific Antibody

    PF-06647020 | New project

    • Phase 1
    • Oncology
    • New Molecular Entity
    • Biologic
    • Current
    NSCLC (Biologic)

    PTK7 Targeted Cytotoxicity

    PF-06821497 | New project

    • Phase 1
    • Oncology
    • New Molecular Entity
    • Small Molecule
    • Current
    Prostate Cancer

    EZH2 Inhibitor

    Ibrance + ARV-471 | New project

    • Phase 2
    • Oncology
    • Product Enhancement
    • Small Molecule
    • Current
    ER+/HER2- Metastatic Breast Cancer

    CDK 4,6 kinase inhibitor ER-targeting PROTAC® protein degrader

    PF-07901801 (TTI-622) | New project

    • Phase 2
    • Oncology
    • New Molecular Entity
    • Biologic
    • Current
    Hematological Malignancies (Biologic)

    CD47-SIRPa Fusion Protein

    Elranatamab | New project

    • Phase 2
    • Oncology
    • New Molecular Entity
    • Biologic
    • Current
    Multiple Myeloma Triple-Class Refractory (Biologic) (BREAKTHROUGH)

    BCMA-CD3 Bispecific Antibody

    ARV-471 | New project

    • Phase 2
    • Oncology
    • New Molecular Entity
    • Small Molecule
    • Current
    ER+/HER2- Metastatic Breast Cancer

    ER-targeting PROTAC® protein degrader

    Braftovi (encorafinib) + Mektovi (binimetinib) | New project

    • Phase 2
    • Oncology
    • Product Enhancement
    • Small Molecule
    • Current
    1st line and 2nd line BRAF-mutant Metastatic Non-Small Cell Lung Cancer

    BRAF kinase inhibitor andMEK inhibitor

    Elranatamab | Project advanced

    • Phase 3
    • Oncology
    • Product Enhancement
    • Biologic
    • Current
    Newly Diagnosed Multiple Myeloma Transplant-Ineligible (Biologic)

    BCMA-CD3 Bispecific Antibody

    Elranatamab | New project

    • Phase 3
    • Oncology
    • Product Enhancement
    • Biologic
    • Current
    Newly Diagnosed Multiple Myeloma Post-Transplant Maintenance (Biologic)

    BCMA-CD3 Bispecific Antibody

    Elranatamab | New project

    • Phase 3
    • Oncology
    • Product Enhancement
    • Biologic
    • Current
    Multiple Myeloma Double-Class Exposed (Biologic)

    BCMA-CD3 Bispecific Antibody

    Braftovi (encorafinib) + Mektovi (binimetinib) + Keytruda®(pembrolizumab) | New project

    • Phase 3
    • Oncology
    • Product Enhancement
    • Small Molecule
    • Current
    BRAF-mutant Metastatic or Unresectable Locally Advanced Melanoma

    BRAF kinase inhibitor andMEK inhibitor and anti PD-1

    Braftovi (encorafinib) + Erbitux® (cetuximab) | New project

    • Phase 3
    • Oncology
    • Product Enhancement
    • Small Molecule
    • Current
    1st line BRAF-mutant Metastatic Colorectal Cancer

    BRAF kinase inhibitor and anti EGFR

    Xtandi (enzalutamide) | New project

    • Phase 3
    • Oncology
    • Product Enhancement
    • Small Molecule
    • Current
    Non-metastatic High-Risk Castration Sensitive Prostate Cancer

    Androgen receptor inhibitor

    Talzenna (talazoparib) | New project

    • Phase 3
    • Oncology
    • Product Enhancement
    • Small Molecule
    • Current
    Combo w/ Xtandi (enzalutamide) for DDR-deficient Metastatic Castration Sensitive Prostate Cancer

    PARP inhibitor

    Talzenna (talazoparib) | New project

    • Phase 3
    • Oncology
    • Product Enhancement
    • Small Molecule
    • Current
    Combo w/ Xtandi (enzalutamide) for 1st Line Metastatic Castration Resistant Prostate Cancer

    PARP inhibitor

    sasanlimab (PF-06801591) + Bacillus Calmette-Guerin (BCG) | New project

    • Phase 3
    • Oncology
    • New Molecular Entity
    • Biologic
    • Current
    Non-Muscle-Invasive Bladder Cancer (Biologic)

    Anti-PD-1

    Ibrance (palbociclib) | New project

    • Phase 3
    • Oncology
    • Product Enhancement
    • Small Molecule
    • Current
    ER+/HER2+ Metastatic Breast Cancer(PATINA)

    CDK 4,6 kinase inhibitor

    Oncology Pipeline as of January 31, 2023
    • 00Phase 1
    • 00Phase 2
    • 00Phase 3
    • 00Registration
    • 00Total

    Oncology Pipeline & Trials